Transthyretin sequesters amyloid beta protein and prevents amyloid formation.

Journal Article (Journal Article)

The cardinal pathological features of Alzheimer disease are depositions of aggregated amyloid beta protein (A beta) in the brain and cerebrovasculature. However, the A beta is found in a soluble form in cerebrospinal fluid in healthy individuals and patients with Alzheimer disease. We postulate that sequestration of A beta precludes amyloid formation. Failure to sequester A beta in Alzheimer disease may result in amyloidosis. When we added A beta to cerebrospinal fluid of patients and controls it was rapidly sequestered into stable complexes with transthyretin. Complexes with apolipoprotein E, which has been shown to bind A beta in vitro, were not observed in cerebrospinal fluid. Additional in vitro studies showed that both purified transthyretin and apolipoprotein E prevent amyloid formation.

Full Text

Duke Authors

Cited Authors

  • Schwarzman, AL; Gregori, L; Vitek, MP; Lyubski, S; Strittmatter, WJ; Enghilde, JJ; Bhasin, R; Silverman, J; Weisgraber, KH; Coyle, PK

Published Date

  • August 30, 1994

Published In

Volume / Issue

  • 91 / 18

Start / End Page

  • 8368 - 8372

PubMed ID

  • 8078889

Pubmed Central ID

  • PMC44607

International Standard Serial Number (ISSN)

  • 0027-8424

Digital Object Identifier (DOI)

  • 10.1073/pnas.91.18.8368


  • eng

Conference Location

  • United States